PIOTR ZIEBA: Open Payments
NPI 1265487631 · FLORENCE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,058 in 168 payments from 19 companies in 2025. Trend: 2023 $3,088 · 2024 $3,191 · 2025 $3,058
Food & beverage: $3,051Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $464 |
| Alkermes, Inc. | 15 | $359 |
| Vanda Pharmaceuticals Inc. | 14 | $346 |
| Lundbeck LLC | 18 | $337 |
| ABBVIE INC. | 13 | $297 |
| Neurocrine BioSciences, Inc. | 14 | $232 |
| Axsome Therapeutics, Inc. | 12 | $178 |
| Teva Pharmaceuticals USA, Inc. | 11 | $172 |
| Janssen Pharmaceuticals, Inc | 8 | $171 |
| Supernus Pharmaceuticals, Inc. | 13 | $144 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, HETLIOZ, INGREZZA, REXULTI, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across KY — which companies pay providers there.
